691 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
ABBV AbbVie Inc. $95.37 $144.42B Buy
Article Searches
Top Ranked Income Stocks to Buy for May 22nd http://www.zacks.com/commentary/417899/top-ranked-income-stocks-to-buy-for-may-22nd?cid=CS-ZC-FT-417899 May 22, 2019 - Top Ranked Income Stocks to Buy for May 22nd
Go Beyond Bargains: Play 5 Stocks With Rising P/E Instead http://www.zacks.com/stock/news/417794/go-beyond-bargains-play-5-stocks-with-rising-p-e-instead?cid=CS-ZC-FT-417794 May 22, 2019 - Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Top Ranked Income Stocks to Buy for May 21st http://www.zacks.com/commentary/417303/top-ranked-income-stocks-to-buy-for-may-21st?cid=CS-ZC-FT-417303 May 21, 2019 - Top Ranked Income Stocks to Buy for May 21st
3 Top Dividend Stocks to Buy Right Now https://www.fool.com/investing/2019/05/21/3-top-dividend-stocks-to-buy-right-now.aspx?source=iedfolrf0000001 May 21, 2019 - If you are looking for income stocks, these high yielders are ripe for the picking.
AbbVie's Brain Cancer Candidate Fails in Phase III Study http://www.zacks.com/stock/news/416716/abbvies-brain-cancer-candidate-fails-in-phase-iii-study?cid=CS-ZC-FT-416716 May 20, 2019 - AbbVie's (ABBV) phase III study on Depatux-M, an investigational candidate for newly diagnosed glioblastoma, fails to show survival benefit in patients receiving Depatux-M.
Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big https://www.fool.com/investing/2019/05/19/top-5-new-drug-launches-of-2019-and-the-biotech-st.aspx?source=iedfolrf0000001 May 19, 2019 - These drugs and the biotechs that make them could be on the way to tremendous success in the near future.
Roche Gets FDA Nod for Venclexta Plus Gazyva to Treat CLL http://www.zacks.com/stock/news/416134/roche-gets-fda-nod-for-venclexta-plus-gazyva-to-treat-cll?cid=CS-ZC-FT-416134 May 17, 2019 - Roche (RHHBY) gains an FDA nod for the sNDA of its leukemia drug, Venclexta, in combination with Gazyva for the treatment of previously untreated chronic lymphocytic leukemia.
Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs http://www.zacks.com/stock/news/415516/pharma-stock-roundup-fda-okays-line-extensions-of-lly-pfe-abbv-cancer-drugs?cid=CS-ZC-FT-415516 May 17, 2019 - FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs
Why AbbVie (ABBV) is a Great Dividend Stock Right Now http://www.zacks.com/stock/news/414365/why-abbvie-abbv-is-a-great-dividend-stock-right-now?cid=CS-ZC-FT-414365 May 15, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
Top Ranked Income Stocks to Buy for May 8th http://www.zacks.com/commentary/410876/top-ranked-income-stocks-to-buy-for-may-8th?cid=CS-ZC-FT-410876 May 08, 2019 - Top Ranked Income Stocks to Buy for May 8th

Pages: 123456...70

Page 1>